Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

Authors

Kevin Joseph Harrington

The Royal Marsden//The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom

Kevin Joseph Harrington , Anthony Kong , Nicolas Mach , Jason Alan Chesney , Beatriz Castelo , Danny Rischin , Ezra E.W. Cohen , Hoi-Shen Radcliffe , Burak Gumuscu , Wendy Snyder , Lillian L. Siu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).

First Author: Kevin J. Harrington

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.

First Author: Zahra Hamedi

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

First Author: Colette Shen

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.

First Author: Jennifer F. De Los Santos